Cardinal Health(US:CAH) ZACKSยท2025-08-12 20:31Core Insights - Cardinal Health reported $60.16 billion in revenue for the quarter ended June 2025, a year-over-year increase of 0.5% and an EPS of $2.08 compared to $1.84 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $60.67 billion, resulting in a surprise of -0.84%, while the EPS exceeded the consensus estimate of $2.03 by +2.46% [1] Revenue Breakdown - Pharmaceutical and Specialty Solutions revenue was $55.37 billion, slightly below the average estimate of $55.86 billion, reflecting a year-over-year decline of -0.4% [4] - Corporate revenue reported at -$21 million, better than the estimated -$21.65 million, but a significant year-over-year decrease of -12.5% [4] - Other revenue reached $1.61 billion, surpassing the average estimate of $1.57 billion, marking a substantial year-over-year increase of +37.3% [4] - Medical Products and Distribution revenue was $3.2 billion, in line with the average estimate of $3.21 billion, showing a year-over-year growth of +2.9% [4] Segment Profit Analysis - Segment profit for Pharmaceutical and Specialty Solutions was $535 million, slightly below the average estimate of $543.86 million [4] - Segment profit for Other was $160 million, exceeding the average estimate of $147.91 million [4] - Global Medical Products and Distribution segment profit was $70 million, above the average estimate of $65.48 million [4] Stock Performance - Cardinal Health's shares have returned -2.5% over the past month, contrasting with the Zacks S&P 500 composite's +2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]